[go: up one dir, main page]

DK3362449T3 - Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose - Google Patents

Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose Download PDF

Info

Publication number
DK3362449T3
DK3362449T3 DK16781455.7T DK16781455T DK3362449T3 DK 3362449 T3 DK3362449 T3 DK 3362449T3 DK 16781455 T DK16781455 T DK 16781455T DK 3362449 T3 DK3362449 T3 DK 3362449T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
disorders associated
sibiriline
derivatives
Prior art date
Application number
DK16781455.7T
Other languages
English (en)
Inventor
Marie-Thérèse Dimanche-Boitrel
Stéphane Bach
Claire Delehouze
Yvette Mettey
Peter Goekjian
Arnaud Comte
Original Assignee
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Univ Poitiers
Univ Claude Bernard Lyon
Univ Sorbonne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Centre Nat Rech Scient, Univ Poitiers, Univ Claude Bernard Lyon, Univ Sorbonne filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of DK3362449T3 publication Critical patent/DK3362449T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10Preservation of living parts
    • A01N1/12Chemical aspects of preservation
    • A01N1/122Preservation or perfusion media
    • A01N1/126Physiologically active agents, e.g. antioxidants or nutrients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
DK16781455.7T 2015-10-13 2016-10-13 Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose DK3362449T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306624 2015-10-13
PCT/EP2016/074638 WO2017064217A1 (en) 2015-10-13 2016-10-13 Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis

Publications (1)

Publication Number Publication Date
DK3362449T3 true DK3362449T3 (da) 2021-07-19

Family

ID=54337712

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16781455.7T DK3362449T3 (da) 2015-10-13 2016-10-13 Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose

Country Status (6)

Country Link
US (1) US10426758B2 (da)
EP (1) EP3362449B1 (da)
DK (1) DK3362449T3 (da)
ES (1) ES2885474T3 (da)
PL (1) PL3362449T3 (da)
WO (1) WO2017064217A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10975064B2 (en) 2018-05-03 2021-04-13 Rigel Pharmaceuticals, Inc. RIP1 inhibitory compounds and methods for making and using the same
EP3788044B1 (en) 2018-05-03 2023-08-09 Rigel Pharmaceuticals, Inc. Rip1 inhibitory compounds and methods for making and using the same
CN111978311B (zh) * 2019-05-21 2024-05-31 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
KR20220042204A (ko) 2019-09-06 2022-04-04 리겔 파마슈티칼스, 인크. Rip1 억제 화합물 및 그를 제조 및 사용하는 방법
JP7493586B2 (ja) 2019-09-06 2024-05-31 ライジェル ファーマシューティカルズ, インコーポレイテッド Rip1阻害化合物ならびにそれを作製および使用するための方法
EP4055021A1 (en) 2019-11-07 2022-09-14 Rigel Pharmaceuticals, Inc. Heterocyclic rip1 inhibitory compounds
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
AR122703A1 (es) 2020-07-01 2022-09-28 Rigel Pharmaceuticals Inc Inhibidores de rip1k
WO2022157392A1 (en) * 2021-01-25 2022-07-28 Seabelife Use of indole, 6- and 7-azaindole derivatives as inhibitors of ferroptosis regulated cell death
AR125587A1 (es) 2021-03-11 2023-08-02 Rigel Pharmaceuticals Inc Inhibidores heterocíclicos de la quinasa de rip1
WO2024115793A1 (en) 2022-12-02 2024-06-06 Seabelife Synergistic combinations of regulated necrosis inhibitors with n-acetylcysteine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
DK2384753T3 (da) 2003-08-29 2016-04-11 Brigham & Womens Hospital Hydantoinderivater som inhibitorer for cellenekrose
JP5244118B2 (ja) * 2006-11-10 2013-07-24 ブリストル−マイヤーズ スクイブ カンパニー 新規キナーゼ阻害剤
US20130059850A1 (en) * 2010-05-06 2013-03-07 Merck Sharp & Dohme Corp. Aza-indole derivatives useful as modulators of faah
LT2935248T (lt) * 2012-12-21 2018-04-10 Plexxikon Inc. Kinazės moduliavimo junginiai ir būdai bei indikacijos
TW201613916A (en) * 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
PL3362450T3 (pl) * 2015-10-13 2021-08-23 Institut National De La Santé Et De La Recherche Médicale (Inserm) N1 i n7-podstawione pochodne sybiriliny oraz ich zastosowania jako inhibitory nekroptozy komórkowej

Also Published As

Publication number Publication date
US20180325876A1 (en) 2018-11-15
US10426758B2 (en) 2019-10-01
PL3362449T3 (pl) 2021-12-13
EP3362449B1 (en) 2021-06-16
ES2885474T3 (es) 2021-12-13
EP3362449A1 (en) 2018-08-22
WO2017064217A1 (en) 2017-04-20

Similar Documents

Publication Publication Date Title
DK3362449T3 (da) Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose
DK3149019T3 (da) Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
DK4014976T3 (da) Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
DK3325509T3 (da) Anti-tfr antistoffer og deres anvendelse i behandling af proliferative og inflammatoriske lidelser
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3134125T3 (da) Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer
DK3102189T3 (da) Sammensætning og fremgangsmåde til at fremme søvn
DK3395353T5 (da) Plasminogen til anvendelse til behandling eller forebyggelse af diabetes-mellitus-nerveskade
DK3395359T3 (da) Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose
DK3303339T3 (da) Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
DK3273995T3 (da) Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion
HK1257169A1 (zh) 用於治療cns和相關疾病的二氫吲哚-2-酮衍生物
DK3310190T3 (da) Sammensætning til behandling af kød og anvendelse af denne
IL247435A0 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
DK3153511T3 (da) 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme
DK3325618T3 (da) Hidtil ukendte trypsin-isoformer og anvendelse deraf
DK3275453T3 (da) Farmaceutisk sammensætning med silibinin og ve
DK3328368T3 (da) Forbindelser og farmaceutisk sammensætning associeret med ubiquitinering-proteasomsystem
DK3187178T3 (da) Sammensætning og lægemidler til reducering af lokaliseret fedt og kropsvægt og anvendelse heraf
HUE057216T2 (hu) Genotípus-rétegzés cukorbetegség kezelésében és megelõzésében
DK3157532T3 (da) Fremgangsmåder til behandling og forebyggelse af sygdomme med vaskulær instabilitet
DK3529234T3 (da) Forbindelser, fremgangsmåde til opnåelse af forbindelserne, farmaceutisk sammensætning, anvendelse af forbindelserne og fremgangsmåde til behandling af psykiatriske lidelser og/eller søvnforstyrrelser
DK3373922T3 (da) Sammensætninger og fremgangsmåder til anvendelse i behandlingen af homocystinuri